XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months

XtalPi-Backed Viva-Thera Advances AI-Designed HIV Candidate to Preclinical Stage in Seven Months

by

In a notable fusion of structural biology and artificial intelligence, biotechnology startup Viva-Thera—incubated and backed by XtalPi—has successfully nominated a preclinical small-molecule drug candidate targeting the membrane-proximal external region of … Read More